Autolus Therapeutics (AUTL) Accumulated Depreciation & Amortization (2017 - 2025)

Autolus Therapeutics (AUTL) has 9 years of Accumulated Depreciation & Amortization data on file, last reported at $8.3 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 9.82% year-over-year to $8.3 million; the trailing twelve-month figure through Dec 2025 stood at $8.3 million (up 9.82% YoY), and the FY2025 full-year result was $8.3 million, up 9.82% from the prior year.
• Accumulated Depreciation & Amortization for Q4 2025 stood at $8.3 million, up from $6.2 million in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at $8.5 million in Q4 2021 and bottomed at $1.8 million in Q1 2024.
• The 5-year median for Accumulated Depreciation & Amortization is $5.6 million (2024), against an average of $5.2 million.
• The widest annual swing landed in 2021, when Accumulated Depreciation & Amortization soared 49.49%; it then fell 17.03% in 2023.
• A 5-year view of Accumulated Depreciation & Amortization shows it stood at $8.5 million in 2021, then slipped by 12.25% to $7.4 million in 2022, then declined by 11.55% to $6.6 million in 2023, then increased by 15.06% to $7.6 million in 2024, then advanced by 9.82% to $8.3 million in 2025.
• The last three Accumulated Depreciation & Amortization figures came in at $8.3 million (Q4 2025), $6.2 million (Q3 2025), and $4.1 million (Q2 2025), per Business Quant data.

Peer Comparison